Does Simoa provide better sensitivity than ELISA or ECL for quantifying neurofilament light chain in blood samples?
Simoa is a highly sensitive technology for quantifying serum neurofilament light chain, outperforming ELISA and ECL assays, and correlating well with CSF levels.
We found Simoa to be more sensitive than ELISA or the ECL assay. Our results support the feasibility of quantifying NfL in serum; the results correlate with the more-established CSF NfL test. The highly sensitive Simoa technology deserves further studies in larger patient cohorts to clarify whether serum NfL could be used in the future to measure disease severity and determine prognosis or response to treatment interventions in neurological diseases.
Kühle et al. (2016) studied this question.